Express News | Vera Therapeutics Inc - to Announce Origin 3 Trial Results in Q2 2025
Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN
Express News | Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 Origin 3 Trial of Atacicept in Igan
Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $107
Cantor Fitzgerald analyst Pete Stavropoulos maintains $Vera Therapeutics(VERA.US)$ with a buy rating, and sets the target price at $107.According to TipRanks data, the analyst has a success rate of 33
Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now